Suryakant Ranjan

Suryakant Ranjan

Biotechnology, Lovely professional University punjab, Phagwāra, India
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
NANahid Akhtar
Nahid Akhtar
JMJorge Samuel S. Leon Magdaleno
Jorge Samuel S. Leon Magdaleno
SRSuryakant Ranjan
Suryakant Ranjan
Atif Khurshid WaniAtif Khurshid Wani
Atif Khurshid Wani
RGRavneet K Grewal
Ravneet K Grewal
MCMohit Chawla
Mohit Chawla
Candida dubliniensis is an opportunistic pathogen associated with oral and invasive fungal infections in immune-compromised individuals. Furthermore, the emergence of C. dubliniensis antifungal drug resistance could exacerbate its treatment. Hence, in this study a multi-epitope vaccine candidate has been designed using an immunoinformatics approach by targeting C. dubliniensis secreted aspartyl proteinases (SAP) proteins. In silico tools have been utilized to predict epitopes and determine their allergic potential, antigenic potential, toxicity, and potential to elicit interleukin-2 (IL2), interleukin-4 (IL4), and IFN-γ. Using the computational tools, eight epitopes have been predicted that were then linked with adjuvants for final vaccine candidate development. Computational immune simulation has depicted that the immunogen designed emerges as a strong immunogenic candidate for a vaccine. Further, molecular docking and molecular dynamics simulation analyses revealed stable interactions between the vaccine candidate and the human toll-like receptor 5 (TLR5). Finally, immune simulations corroborated the promising candidature of the designed vaccine, thus calling for further in vivo investigation.